HESTAR-200 PENTASTARCH 10%

B05AA07(WHO) 9005-27-0Y 17340832Y 875Y4127EA DTXSID3046829 Interactive image O(CCO)[C@H]1O[C@@H]([C@@H](OCCO)[C@H](OCCO)[C@H]1OCCO)COCCO.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O InChI=1S/C16H32O11.C6H12O6/c17-1-6-22-11-12-13(23-7-2-18)14(24-8-3-19)15(25-9-4-20)16(27-12)26-10-5-21;7-1-2-3(8)4(9)5(10)6(11)12-2/h12-21H,1-11H2;2-11H,1H2/t12-,13-,1​‍​​​​​‍​‍‍‍‍​‍‍4+,15-,16+;2-,3-,4+,5-,6+/m11/s1YKey:DNZMDASEFMLYBU-RNBXVSKKSA-NY Hydroxyethyl starch(HES/HAES), sold under the brand nameVoluvenamong others, is a nonionicstarch derivative, used as avolume expanderinintravenous therapy. The use of HES on critically ill patients is associated with an increased risk of death and kidney problems. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.TheEuropean Medicines Agencycommenced in June 2013 the process of agreeing to reduced indications which was completed in October 2013.The process of full withdrawal in the EU was expected to complete in 2018.